Entrada Therapeutics (Entrada Therapeutics) Cash-to-Debt : 5.16 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Entrada Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Entrada Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 5.16.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Entrada Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Entrada Therapeutics's Cash-to-Debt or its related term are showing as below:

TRDA' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.16 Med: No Debt Max: No Debt
Current: 5.16

During the past 5 years, Entrada Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 5.16. And the median was No Debt.

TRDA's Cash-to-Debt is ranked worse than
53.74% of 1539 companies
in the Biotechnology industry
Industry Median: 6.46 vs TRDA: 5.16

Entrada Therapeutics Cash-to-Debt Historical Data

The historical data trend for Entrada Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Entrada Therapeutics Cash-to-Debt Chart

Entrada Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

7.28

5.16

Entrada Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial											7.28	25.37	5.16	5.12	5.16

Competitive Comparison of Entrada Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Entrada Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entrada Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's Cash-to-Debt falls into.

Entrada Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Entrada Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	351.969	/	(7.909	+	60.321)
	=	5.16

Entrada Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	351.969	/	(7.909	+	60.321)
	=	5.16

Entrada Therapeutics (NAS:TRDA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Entrada Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Entrada Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Entrada Therapeutics (Entrada Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entrada Therapeutics Inc (NAS:TRDA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Tide Street, Boston, MA, USA, 02210

Website

https://www.entradatx.com

Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.

Executives

Dipal Doshi	director, officer: President and CEO	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Kory James Wentworth	officer: Chief Financial Officer	6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210
Nathan J Dowden	officer: Chief Operating Officer	6 TIDE STREET, BOSTON MA 02210
Nerissa Kreher	officer: Chief Medical Officer	C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Gina Chapman	director	C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403
Natarajan Sethuraman	officer: Chief Scientific Officer	6 TIDE STREET, BOSTON MA 02210
Bernhardt G Zeiher	director	ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210
Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Todd Foley	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Felix Baker	10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
John F Crowley	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Mpm Bioventures 2018, L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142